Health Italia Valuation
Is HI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HI?
Key metric: As HI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is HI's PE Ratio? | |
|---|---|
| PE Ratio | 14.6x |
| Earnings | €1.69m |
| Market Cap | €24.59m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 3.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does HI's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.8x | ||
EUK EuKedos | 26.6x | n/a | €19.1m |
SRI Servizi Italia | 14.8x | 16.9% | €69.0m |
IMD I.M.D. International Medical Devices | 9.7x | 18.6% | €24.9m |
IVN iVision Tech | 0.03x | -111.5% | €16.2m |
HI Health Italia | 14.6x | n/a | €24.6m |
Price-To-Earnings vs Peers: HI is expensive based on its Price-To-Earnings Ratio (14.6x) compared to the peer average (12.8x).
Price to Earnings Ratio vs Industry
How does HI's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: HI is good value based on its Price-To-Earnings Ratio (14.6x) compared to the European Healthcare industry average (18.7x).
Price to Earnings Ratio vs Fair Ratio
What is HI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HI's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fresenius Medical Care
€12.6b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
1FME
€42.80
7D
2.6%
1Y
16.5%
Garofalo Health Care
€515.4m
Operates healthcare clinics in Italy.
GHC
€5.82
7D
0.7%
1Y
27.9%
Amplifon
€5.3b
Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
AMP
€23.33
7D
-1.5%
1Y
-18.5%